The EU Paediatric Regulation: Still a Large Discrepancy Between Therapeutic Needs and Approved Paediatric Investigation Plans

Pediatric Drugs

Volumn 16, Issue 5, 2014, Pages 397-406

  Wimmer, Stefan ^a   Rascher, Wolfgang ^a   McCarthy, Suzanne ^b   Neubert, Antje ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; DRUG APPROVAL; EUROPEAN UNION; HUMAN; LEGISLATION AND JURISPRUDENCE; PATENT; PEDIATRICS;

CHILD; DRUG APPROVAL; EUROPEAN UNION; HUMANS; PATENTS AS TOPIC; PEDIATRICS;

EID: 84922059911     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0082-4     Document Type: Article

References (25)

1. Shirkey H. Therapeutic orphans. J Pediatr. 1968;72(1):119–20.
2. Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104(3 Pt 2):585–90.
3. Congress of the United States of America (1997) Food and Drug Administration Modernization Act of 1997. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct. Accessed 23 May 2014.
4. Congress of the United States of America (2002) Best Pharmaceuticals for Children Act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct. Accessed 23 May 2014.
5. Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, et al. Stimulation programs for pediatric drug research: do children really benefit? Eur J Pediatr. 2007;166(8):849–55.
6. Grieve J, Tordoff J, Reith D, Norris P. Effect of the pediatric exclusivity provision on children’s access to medicines. Br J Clin Pharmacol. 2005;59(6):730–5.
7. The European Parliament and the Council of the European Union (2006) Paeditric Regulation (EC No 1901/2006). http://ec.europa.eu/health/human-use/paediatric-medicines/index_en.htm. Accessed 27 May 2014.
8. European Medicines Agency (2013) Paediatric needs. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000096.jsp. Data Retrieved 29 August 2013.
9. European Medicines Agency (2004) Preliminary list of priorities for paediatric studies of medicinal products (EMEA/2850/04).
10. European Medicines Agency (2013) Revised provisional priority list for studies into off-patent paediatric medicinal products (EMA/98717/2012 Rev. 2013/14) and former versions. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000092.jsp. Accessed 27 May 2014.
11. European Medicines Agency (2011) Decision on a class waiver on condition(s) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council CW/1/2011 (EMA/973755/2011). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000036.jsp. Accessed 27 May 2014.
12. European Medicines Agency (2012) 5-year Report to the European Commission: General report on the experience acquired as a result of the application of the Paediatric Regulation (EMA/428172/2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000068.jsp. Accessed 27 May 2014.
13. Community Research and Development Information Service (CORDIS) (2013) Seventh Framework Programme (FP7). http://cordis.europa.eu/fp7/projects_en.html. Data retrieved 23 August 2013.
14. European Medicines Agency (2013) Opinions and decisions on paediatric investigation plans. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip_search.jsp. Data retrieved 23 August 2013.
15. European Medicines Agency (2011) Report to the European Commission on companies and products that have benefited from any of the rewards and incentives in the Paediatric Regulation and on the companies that have failed to comply with any of the obligations in this Regulation, covering the year 2011(EMA/480331/2012 Corr. 12 September 2012). http://ec.europa.eu/health/files/paediatrics/2012-07_paediatric_regulations.pdf. Accessed 27 May 2014.
16. Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168(2):130–6.
17. Haslund-Krog S, Mathiasen R, Christensen HR, Holst H. The impact of legislation on drug substances used off-label in paediatric wards-a nationwide study. Eur J Clin Pharmacol. 2014;70(4):445–52.
18. Male C. Bessere Arzneimittel für Kinder - Wie viel hat die „Paediatric Regulation“ der EU nach 5 Jahren erreicht? Monatsschr Kinderheilkd. 2013;161(4):301–7.
19. Davies EH, Ollivier CM, Saint Raymond A. Paediatric investigation plans for pain: painfully slow! Eur J Clin Pharmacol. 2010;66(11):1091–7.
20. Baker-Smith CM, Benjamin DK Jr, Grabowski HG, Reid ED, Mangum B, Goldsmith JV, et al. The economic returns of pediatric clinical trials of antihypertensive drugs. Am Heart J. 2008;156(4):682–8.
21. Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007;297(5):480–8.
22. The European Parliament and the Council of the European Union (2001) The Clinical Trials Directive (2001/20/EC). http://ec.europa.eu/health/human-use/clinical-trials. Accessed 27 May 2014.
23. Co-ordination Group for Mutual Recognition and Decentralised Procedures (2014) Paediatric Regulation Guidance Documents. http://www.hma.eu/216.html. Accessed 04 April 2014.
24. European Commission (2013) Better Medicines for Children: From Concept to Reality - Progress Report on the Paediatric Regulation (EC) N°1901/2006 (COM (2013) 443). http://ec.europa.eu/health/highlights/2012/35/. Accessed 27 May 2014.
25. European Medicines Agency (2014) Press Release: European Medicines Agency gives second positive opinion for a paediatric-use marketing authorisation (EMA/99224/2014). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/02/news_detail_002030.jsp. Accessed 27 May 2014.